Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review
Annals of Hematology · 2024-03 · 103 (3) · 999-1005
DOI: 10.1007/s00277-024-05633-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 29.01.2024. Verfasst von Qiuyan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China. Hauptthemen laut MEDLINE: Skin Neoplasms, Hematologic Neoplasms, Myeloproliferative Disorders, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is highly aggressive with a poor prognosis. There is no standard treatment for BPDCN. Although conventional chemotherapies are usually sensitive in the initial therapy, relapse and drug resistance are inevitable within a short duration. Targeted therapies have enlightened new prospects for the treatment of BPDCN, especially for those in a frail state and intolerable to standard chemotherapies or hematopoietic stem cell transplantation. Here, we report an 82-year-old man diagnosed with cutaneous-limited BPDCN. Considering the old age and limited involvement of the tumor, we reduced the dosage of venetoclax. His skin lesions subsided significantly after 1 cycle of azacytidine (100 mg d1-7) combined with reduced doses of venetoclax (200 mg d1-14). The reduction in the dose of venetoclax avoided severe myelosuppression while achieving satisfactory outcomes. The patient received 2 cycles of therapy with no skin lesions re-occurred for 7 months before relapsing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China.
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
- Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
- Shandong Provincial Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
- Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China. liuxingrant@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q., Zhao, Y., Zang, X., Zhou, G., Liu, Y., Feng, Q., Li, X., Wang, W., Dong, X., Liu, X., Peng, J., & Liu, C. (2024). Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Annals of Hematology, 103(3), 999-1005. https://doi.org/10.1007/s00277-024-05633-y
Vancouver
Wang Q, Zhao Y, Zang X, Zhou G, Liu Y, Feng Q, et al. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Annals of Hematology. 2024;103(3):999-1005. doi:10.1007/s00277-024-05633-y
BibTeX
@article{Wang2024,
author = {Wang, Qiuyan and Zhao, Yajing and Zang, Xiao and Zhou, Guizhi and Liu, Yongxia and Feng, Qi and Li, Xin and Wang, Wen and Dong, Xiaoyuan and Liu, Xinguang and Peng, Jun and Liu, Chuanfang},
title = {Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {3},
pages = {999--1005},
doi = {10.1007/s00277-024-05633-y}
}
EUVIMED